Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)

Background: BRAF(V600E) mutation is present in a subset of pediatric brain tumors. Vemurafenib is an oral, selective ATP-competitive inhibitor of BRAF(V600E) kinase. The goal of this multi-center study conducted through the Pacific Pediatric Neuro-Oncology Consortium (PNOC) was to determine the reco...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Nicolaides, Theodore, Nazemi, Kellie J., Crawford, John, Kilburn, Lindsay, Minturn, Jane, Gajjar, Amar, Gauvain, Karen, Leary, Sarah, Dhall, Girish, Aboian, Mariam, Robinson, Giles, Long-Boyle, Janel, Wang, Hechuan, Molinaro, Annette M., Mueller, Sabine, Prados, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2020
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260122/
https://ncbi.nlm.nih.gov/pubmed/32523649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27600
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky